Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database

Kathy Petoumenos; C. Ringland; R. Goodman; M. Gotowski; D. Couldwell; L. Lewis; D. Austin; M. Block; D. Quan; A. Gowers; K. Brown; N. Skobalj; C. O'Connor; M. Mitchell; D. Templeton; M. T. Liang; D. Allen; B. Strazdinis; B. Mulhall; D. Smith; K. Mutimer; J. Armishaw; D. Cooper; A. Carr; M. Lacey; C. Pell; R. Rohrsheim; R. Finlayson; R. Richardson; D. Ellis; D. Baker; J. Kidd; R. McFarlane; R. Vale; P. Canavan; M. Law; D. Smith; S. Huffam; J. Savage; S. Morgan; P. Knibbs; G. Rogers; S. Markinson; C. Sullivan; F. Downey; M. Curry; J. Oddy; J. Thompson; H. Ree; H. Magon; D. Sowden; A. Walker; D. Orth; G. Lister; D. Youds; J. Chuah; R. James; W. Frankhauser; B. Dickson; D. Bradford; J. Leamy; C. D'Arcy Evans; T. Reid; J. Laing; I. Woolley; T. Korman; A. Padiglione; K. Visvanathan; N. Roth; B. Eu; S. Strecker; D. Russell; H. Wood; A. Mijch; J. Hoy; A. Pierce; C. McCormack; K. Watson; J. Anderson; R. Moore; D. Russell; G. McGovern; R. McNair; K. Lowe; J. Bal; N. Medland; S. Mallal; M. French; J. Skett; C. Moore

doi:10.1111/j.1468-1293.2005.00280.x

Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database

Kathy Petoumenos, C. Ringland, R. Goodman, M. Gotowski, D. Couldwell, L. Lewis, D. Austin, M. Block, D. Quan, A. Gowers, K. Brown, N. Skobalj, C. O'Connor, M. Mitchell, D. Templeton, M. T. Liang, D. Allen, B. Strazdinis, B. Mulhall, D. SmithK. Mutimer, J. Armishaw, D. Cooper, A. Carr, M. Lacey, C. Pell, R. Rohrsheim, R. Finlayson, R. Richardson, D. Ellis, D. Baker, J. Kidd, R. McFarlane, R. Vale, P. Canavan, M. Law, D. Smith, S. Huffam, J. Savage, S. Morgan, P. Knibbs, G. Rogers, S. Markinson, C. Sullivan, F. Downey, M. Curry, J. Oddy, J. Thompson, H. Ree, H. Magon, D. Sowden, A. Walker, D. Orth, G. Lister, D. Youds, J. Chuah, R. James, W. Frankhauser, B. Dickson, D. Bradford, J. Leamy, C. D'Arcy Evans, T. Reid, J. Laing, I. Woolley, T. Korman, A. Padiglione, K. Visvanathan, N. Roth, B. Eu, S. Strecker, D. Russell, H. Wood, A. Mijch, J. Hoy, A. Pierce, C. McCormack, K. Watson, J. Anderson, R. Moore, D. Russell, G. McGovern, R. McNair, K. Lowe, J. Bal, N. Medland, S. Mallal, M. French, J. Skett, C. Moore

Research output: Contribution to journal › Article › peer-review

Abstract

Objectives: To assess the impact of highly active antiretroviral therapy (HAART) on rates of change of antiretroviral treatment among patients co-infected with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) in the Australian HIV Observational Database (AHOD). Methods: Analysis was based on 805 of the 2218 patients recruited to the AHOD by March 2003, who had commenced HAART after 1 January 1997, who had recorded test results for HBV surface antigen and anti-HCV antibody, and who had follow-up of more than 3 months. The effect of hepatitis co-infection on the rate of antiretroviral treatment change after commencing HAART was assessed using a random-effect Poisson regression model. Results: Among those included in the analyses, the prevalences of HBV and HCV were 4.8% and 12.8%, respectively. The overall rate of combination antiretroviral treatment change was 0.74 combinations per year. Factors independently associated with an increased rate of change of combination antiretroviral treatment were: prior AIDS-defining illness; prior exposure to double combination antiretroviral therapy; and antiretroviral treatment class. Co-infection with HBV and/or HCV was not found to be significantly associated with the rate of combination antiretroviral treatment change. Conclusions: While both HBV and HCV co-infections are relatively common in the AHOD, they do not appear to be serious impediments to the treatment of HIV-infected patients.

Original language	English (US)
Pages (from-to)	155-163
Number of pages	9
Journal	HIV Medicine
Volume	6
Issue number	3
DOIs	https://doi.org/10.1111/j.1468-1293.2005.00280.x
State	Published - May 2005
Externally published	Yes

Keywords

Antiretroviral
Co-infection
Hepatitis B virus
Hepatitis C virus
HIV

ASJC Scopus subject areas

Health Policy
Infectious Diseases
Pharmacology (medical)

Access to Document

10.1111/j.1468-1293.2005.00280.x

Cite this

Petoumenos, K., Ringland, C., Goodman, R., Gotowski, M., Couldwell, D., Lewis, L., Austin, D., Block, M., Quan, D., Gowers, A., Brown, K., Skobalj, N., O'Connor, C., Mitchell, M., Templeton, D., Liang, M. T., Allen, D., Strazdinis, B., Mulhall, B., ... Moore, C. (2005). Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database. HIV Medicine, 6(3), 155-163. https://doi.org/10.1111/j.1468-1293.2005.00280.x

Petoumenos, K, Ringland, C, Goodman, R, Gotowski, M, Couldwell, D, Lewis, L, Austin, D, Block, M, Quan, D, Gowers, A, Brown, K, Skobalj, N, O'Connor, C, Mitchell, M, Templeton, D, Liang, MT, Allen, D, Strazdinis, B, Mulhall, B, Smith, D, Mutimer, K, Armishaw, J, Cooper, D, Carr, A, Lacey, M, Pell, C, Rohrsheim, R, Finlayson, R, Richardson, R, Ellis, D, Baker, D, Kidd, J, McFarlane, R, Vale, R, Canavan, P, Law, M, Smith, D, Huffam, S, Savage, J, Morgan, S, Knibbs, P, Rogers, G, Markinson, S, Sullivan, C, Downey, F, Curry, M, Oddy, J, Thompson, J, Ree, H, Magon, H, Sowden, D, Walker, A, Orth, D, Lister, G, Youds, D, Chuah, J, James, R, Frankhauser, W, Dickson, B, Bradford, D, Leamy, J, D'Arcy Evans, C, Reid, T, Laing, J, Woolley, I, Korman, T, Padiglione, A, Visvanathan, K, Roth, N, Eu, B, Strecker, S, Russell, D, Wood, H, Mijch, A, Hoy, J, Pierce, A, McCormack, C, Watson, K, Anderson, J, Moore, R, Russell, D, McGovern, G, McNair, R, Lowe, K, Bal, J, Medland, N, Mallal, S, French, M, Skett, J & Moore, C 2005, 'Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database', HIV Medicine, vol. 6, no. 3, pp. 155-163. https://doi.org/10.1111/j.1468-1293.2005.00280.x

@article{3da0a3cb5af54f6ab000fd5921af6c9c,

title = "Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database",

abstract = "Objectives: To assess the impact of highly active antiretroviral therapy (HAART) on rates of change of antiretroviral treatment among patients co-infected with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) in the Australian HIV Observational Database (AHOD). Methods: Analysis was based on 805 of the 2218 patients recruited to the AHOD by March 2003, who had commenced HAART after 1 January 1997, who had recorded test results for HBV surface antigen and anti-HCV antibody, and who had follow-up of more than 3 months. The effect of hepatitis co-infection on the rate of antiretroviral treatment change after commencing HAART was assessed using a random-effect Poisson regression model. Results: Among those included in the analyses, the prevalences of HBV and HCV were 4.8% and 12.8%, respectively. The overall rate of combination antiretroviral treatment change was 0.74 combinations per year. Factors independently associated with an increased rate of change of combination antiretroviral treatment were: prior AIDS-defining illness; prior exposure to double combination antiretroviral therapy; and antiretroviral treatment class. Co-infection with HBV and/or HCV was not found to be significantly associated with the rate of combination antiretroviral treatment change. Conclusions: While both HBV and HCV co-infections are relatively common in the AHOD, they do not appear to be serious impediments to the treatment of HIV-infected patients.",

keywords = "Antiretroviral, Co-infection, Hepatitis B virus, Hepatitis C virus, HIV",

author = "Kathy Petoumenos and C. Ringland and R. Goodman and M. Gotowski and D. Couldwell and L. Lewis and D. Austin and M. Block and D. Quan and A. Gowers and K. Brown and N. Skobalj and C. O'Connor and M. Mitchell and D. Templeton and Liang, {M. T.} and D. Allen and B. Strazdinis and B. Mulhall and D. Smith and K. Mutimer and J. Armishaw and D. Cooper and A. Carr and M. Lacey and C. Pell and R. Rohrsheim and R. Finlayson and R. Richardson and D. Ellis and D. Baker and J. Kidd and R. McFarlane and R. Vale and P. Canavan and M. Law and D. Smith and S. Huffam and J. Savage and S. Morgan and P. Knibbs and G. Rogers and S. Markinson and C. Sullivan and F. Downey and M. Curry and J. Oddy and J. Thompson and H. Ree and H. Magon and D. Sowden and A. Walker and D. Orth and G. Lister and D. Youds and J. Chuah and R. James and W. Frankhauser and B. Dickson and D. Bradford and J. Leamy and {D'Arcy Evans}, C. and T. Reid and J. Laing and I. Woolley and T. Korman and A. Padiglione and K. Visvanathan and N. Roth and B. Eu and S. Strecker and D. Russell and H. Wood and A. Mijch and J. Hoy and A. Pierce and C. McCormack and K. Watson and J. Anderson and R. Moore and D. Russell and G. McGovern and R. McNair and K. Lowe and J. Bal and N. Medland and S. Mallal and M. French and J. Skett and C. Moore",

year = "2005",

month = may,

doi = "10.1111/j.1468-1293.2005.00280.x",

language = "English (US)",

volume = "6",

pages = "155--163",

journal = "HIV Medicine",

issn = "1464-2662",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "3",

}

TY - JOUR

T1 - Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database

AU - Petoumenos, Kathy

AU - Ringland, C.

AU - Goodman, R.

AU - Gotowski, M.

AU - Couldwell, D.

AU - Lewis, L.

AU - Austin, D.

AU - Block, M.

AU - Quan, D.

AU - Gowers, A.

AU - Brown, K.

AU - Skobalj, N.

AU - O'Connor, C.

AU - Mitchell, M.

AU - Templeton, D.

AU - Liang, M. T.

AU - Allen, D.

AU - Strazdinis, B.

AU - Mulhall, B.

AU - Smith, D.

AU - Mutimer, K.

AU - Armishaw, J.

AU - Cooper, D.

AU - Carr, A.

AU - Lacey, M.

AU - Pell, C.

AU - Rohrsheim, R.

AU - Finlayson, R.

AU - Richardson, R.

AU - Ellis, D.

AU - Baker, D.

AU - Kidd, J.

AU - McFarlane, R.

AU - Vale, R.

AU - Canavan, P.

AU - Law, M.

AU - Smith, D.

AU - Huffam, S.

AU - Savage, J.

AU - Morgan, S.

AU - Knibbs, P.

AU - Rogers, G.

AU - Markinson, S.

AU - Sullivan, C.

AU - Downey, F.

AU - Curry, M.

AU - Oddy, J.

AU - Thompson, J.

AU - Ree, H.

AU - Magon, H.

AU - Sowden, D.

AU - Walker, A.

AU - Orth, D.

AU - Lister, G.

AU - Youds, D.

AU - Chuah, J.

AU - James, R.

AU - Frankhauser, W.

AU - Dickson, B.

AU - Bradford, D.

AU - Leamy, J.

AU - D'Arcy Evans, C.

AU - Reid, T.

AU - Laing, J.

AU - Woolley, I.

AU - Korman, T.

AU - Padiglione, A.

AU - Visvanathan, K.

AU - Roth, N.

AU - Eu, B.

AU - Strecker, S.

AU - Russell, D.

AU - Wood, H.

AU - Mijch, A.

AU - Hoy, J.

AU - Pierce, A.

AU - McCormack, C.

AU - Watson, K.

AU - Anderson, J.

AU - Moore, R.

AU - Russell, D.

AU - McGovern, G.

AU - McNair, R.

AU - Lowe, K.

AU - Bal, J.

AU - Medland, N.

AU - Mallal, S.

AU - French, M.

AU - Skett, J.

AU - Moore, C.

PY - 2005/5

Y1 - 2005/5

N2 - Objectives: To assess the impact of highly active antiretroviral therapy (HAART) on rates of change of antiretroviral treatment among patients co-infected with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) in the Australian HIV Observational Database (AHOD). Methods: Analysis was based on 805 of the 2218 patients recruited to the AHOD by March 2003, who had commenced HAART after 1 January 1997, who had recorded test results for HBV surface antigen and anti-HCV antibody, and who had follow-up of more than 3 months. The effect of hepatitis co-infection on the rate of antiretroviral treatment change after commencing HAART was assessed using a random-effect Poisson regression model. Results: Among those included in the analyses, the prevalences of HBV and HCV were 4.8% and 12.8%, respectively. The overall rate of combination antiretroviral treatment change was 0.74 combinations per year. Factors independently associated with an increased rate of change of combination antiretroviral treatment were: prior AIDS-defining illness; prior exposure to double combination antiretroviral therapy; and antiretroviral treatment class. Co-infection with HBV and/or HCV was not found to be significantly associated with the rate of combination antiretroviral treatment change. Conclusions: While both HBV and HCV co-infections are relatively common in the AHOD, they do not appear to be serious impediments to the treatment of HIV-infected patients.

AB - Objectives: To assess the impact of highly active antiretroviral therapy (HAART) on rates of change of antiretroviral treatment among patients co-infected with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) in the Australian HIV Observational Database (AHOD). Methods: Analysis was based on 805 of the 2218 patients recruited to the AHOD by March 2003, who had commenced HAART after 1 January 1997, who had recorded test results for HBV surface antigen and anti-HCV antibody, and who had follow-up of more than 3 months. The effect of hepatitis co-infection on the rate of antiretroviral treatment change after commencing HAART was assessed using a random-effect Poisson regression model. Results: Among those included in the analyses, the prevalences of HBV and HCV were 4.8% and 12.8%, respectively. The overall rate of combination antiretroviral treatment change was 0.74 combinations per year. Factors independently associated with an increased rate of change of combination antiretroviral treatment were: prior AIDS-defining illness; prior exposure to double combination antiretroviral therapy; and antiretroviral treatment class. Co-infection with HBV and/or HCV was not found to be significantly associated with the rate of combination antiretroviral treatment change. Conclusions: While both HBV and HCV co-infections are relatively common in the AHOD, they do not appear to be serious impediments to the treatment of HIV-infected patients.

KW - Antiretroviral

KW - Co-infection

KW - Hepatitis B virus

KW - Hepatitis C virus

KW - HIV

UR - http://www.scopus.com/inward/record.url?scp=21144436792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21144436792&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1293.2005.00280.x

DO - 10.1111/j.1468-1293.2005.00280.x

M3 - Article

C2 - 15876281

AN - SCOPUS:21144436792

SN - 1464-2662

VL - 6

SP - 155

EP - 163

JO - HIV Medicine

JF - HIV Medicine

IS - 3

ER -

Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this